Advertisement

Topics

Cardiomyopathy - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Cardiomyopathy - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 113-page report is available in PDF from $2000.

Cardiomyopathy - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Cardiomyopathy - Pipeline Review, H1 2015’, provides an overview of the Cardiomyopathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cardiomyopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cardiomyopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cardiomyopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cardiomyopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cardiomyopathy Overview 9
Therapeutics Development 10
Pipeline Products for Cardiomyopathy - Overview 10
Pipeline Products for Cardiomyopathy - Comparative Analysis 11
Cardiomyopathy - Therapeutics under Development by Companies 12
Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 14
Cardiomyopathy - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Cardiomyopathy - Products under Development by Companies 18
Cardiomyopathy - Products under Investigation by Universities/Institutes 20
Cardiomyopathy - Companies Involved in Therapeutics Development 21
Array BioPharma Inc. 21
Beech Tree Labs, Inc. 22
Bioheart, Inc. 23
Celladon Corporation 24
Gilead Sciences, Inc. 25
Kasiak Research Pvt. Ltd. 26
LG Life Sciences, Ltd. 27
miRagen Therapeutics, Inc. 28
MyoKardia, Inc. 29
Neurimmune Holding AG 30
Novartis AG 31
Nyken BV 32
Sanofi 33
Shire Plc 34
Stemedica Cell Technologies, Inc. 35
Stempeutics Research Private Limited 36
Torrent Pharmaceuticals Limited 37
Vericel Corporation 38
Cardiomyopathy - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
AdipoCell - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ARRY-797 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
binimetinib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CAP-1002 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cyndacel-M - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug for Cardiomyopathy - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Gene Therapy for Cardiomyopathy - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Gene therapy to Activate mSCF for Ischemic Cardiomyopathy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GLP-1 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GS-6615 - Drug Profile 65
Product Description 65
Mechanism of Action 65
For more information open Cardiomyopathy - Pipeline Review, H1 2015.

SKU: GMDHC6263IDB

Original Article: Cardiomyopathy - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Cardiomyopathy - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...